Stromal reprogramming overcomes resistance to RAS-MAPK inhibition to improve pancreas cancer responses to cytotoxic and immune therapy.
Liu X, Baer JM, Stone ML, Knolhoff BL, Hogg GD, Turner MC, Kao YL, Weinstein AG, Ahmad F, Chen J, Schmidt AD, Klomp JA, Coho H, Coho KS, Coma S, Pachter JA, Bryant KL, Kang LI, Lim KH, Beatty GL, DeNardo DG.
Liu X, et al. Among authors: stone ml.
Sci Transl Med. 2024 Oct 23;16(770):eado2402. doi: 10.1126/scitranslmed.ado2402. Epub 2024 Oct 23.
Sci Transl Med. 2024.
PMID: 39441902